Faruqi & Faruqi Alerts Investors About Hims & Hers Class Action Lawsuit Deadlines

Faruqi & Faruqi Reminds Investors of Hims & Hers Class Action Lawsuit



Faruqi & Faruqi, LLP, a well-respected securities law firm in the United States, is actively investigating potential claims against Hims & Hers Health, Inc. (NYSE: HIMS). The firm has issued a reminder to investors regarding the upcoming deadline for becoming a lead plaintiff in a federal securities class action against the Company, which has been set for August 25, 2025. Those who acquired securities in Hims between April 29, 2025, and June 22, 2025, are encouraged to reach out to discuss their legal rights and options.

The recent announcement surrounding Hims indicates troubling allegations concerning their business practices. According to the complaint, Hims and its executives are accused of violating federal securities laws. The firm alleges that misleading statements were made and critical information was omitted, leading to investor losses. More specifically, the claims state that Hims engaged in the “deceptive promotion and selling” of illegitimate versions of Wegovy®, a drug closely monitored for safety, putting patients at risk.

By not disclosing the risk of termination of their partnership with Novo Nordisk, the reliability of the Company's once-promising ventures came into question. This partnership ended abruptly on June 23, 2025, when Novo Nordisk announced it was withdrawing due to Hims' failure to comply with legal requirements regarding drug sales. Such breach placed patients in potential unsafe situations due to the questionable nature of the “semaglutide” ingredients in the products sold through telehealth services.

As a direct result of this unsettling information being made public, Hims& Hers’ stock plummeted 34.6%, dropping by $22.24 to close at $41.98 per share on the announcement date. These drastic changes have prompted many investors to seek legal counsel to understand their rights under the current circumstances.

The role of a lead plaintiff in a class action suit is crucial, as the lead plaintiff is responsible for directing and overseeing the litigation process on behalf of all affected investors. Any members of the affected group can apply to be the lead plaintiff through their chosen legal representation or remain as absent class members, which won’t influence their ability to participate in any potential recovery from the lawsuit.

Faruqi & Faruqi also welcomes information from anyone who possesses details about the actions taken by Hims. This includes whistleblowers, employees, former employees, shareholders, and other parties who can shed light on the situation. This engagement is vital as it could influence the outcome of the case and aid in bringing those responsible for potential wrongdoing to justice.

If you believe you have a claim against Hims & Hers Health or wish to discuss this matter in more detail, you can reach out directly to Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Details about this class action suit can also be accessed through Faruqi & Faruqi’s dedicated website linked for investors navigating this complex legal landscape. Learn More Here.

This situation reflects broader issues within the healthcare and telehealth industries, reminding investors and consumers alike of the importance of transparency and ethical business practices. Faruqi & Faruqi is committed to advocating for investor rights and ensuring that those harmed by possibly deceitful business conduct can seek justice. As the deadline approaches, it remains imperative for those impacted to consult with knowledgeable legal counsel to explore their options and rights in this evolving case.

Conclusion



The legal implications of this lawsuit are still unfolding, and stakeholders are encouraged to stay informed as more details emerge. Hims & Hers Health faces monumental challenges showcasing its adherence to laws governing pharmaceutical practices in light of recent allegations. Investors should act promptly to protect their interests as this class action progresses.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.